Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤Immunic granted inducement options covering 12,900 shares to three new employees.
- ➤Options vest 25% after one year, then monthly over 36 installments.
- ➤Vidofludimus calcium Phase 3 relapsing MS data expected by end of 2026.
- ➤Additional Phase 3 progressive MS trial expected to begin later in 2026.
Immunic Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced that on October 1, 2026, the Compensation Committee of Immunic's Board of Directors granted inducement equity grants covering an aggregate of 12,900 shares of common stock of the company under the Immunic, Inc. 2026 Inducement Equity Compensation Plan (the "Options") to three new employees. The Options were granted as an inducement material to the commencement of employment pursuant to NASDAQ Listing Rule 5635(c)(4). The Options will be time vested, with 25% vesting on the first anniversary of the applicable date of hire of each individual and the remainder vesting on a monthly basis in 36 equal installments, subject to each such employee's continued employment on each vesting date.
Get started
Create a free account to read the full story.